COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Retrospectively registered

Titles & IDs
Public title
Effect of the dietary supplement Satisfax (Registered Trademark) on weight loss in overweight volunteers.
Scientific title
Effect of the dietary supplement Satisfax (Registered Trademark) on weight loss in overweight volunteers.
Secondary ID [1] 285438 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Overweight/obesity 293198 0
Condition category
Condition code
Diet and Nutrition 293474 293474 0 0

Study type
Description of intervention(s) / exposure
Intervention with Satisfax (Registered Trademark), a proprietary blend of grape and kiwifruit extract, 3 times a day prior to meals at a dose of of 2 capsules (1 gram). The treatment will be administered for 8 weeks via an oral capsule. Adherence to the treatment regime will be monitored by capsule bottle return and self reporting on line.
Intervention code [1] 290371 0
Treatment: Drugs
Comparator / control treatment
No treatment. The participant's weight during the intervention will be compared to their weight immediately prior to the intervention.
Control group

Primary outcome [1] 293293 0
Body weight recorded on calibrated scales.
Timepoint [1] 293293 0
Eight weeks
Primary outcome [2] 293446 0
Acceptability of the treatment assessed by participants completing a 5 point Likert Scale.
Timepoint [2] 293446 0
8 weeks
Primary outcome [3] 293447 0
Compliance with prescribed dose assessed by participants returning their capsule bottles and the remaining capsules counted and recorded.
Timepoint [3] 293447 0
8 weeks
Secondary outcome [1] 310992 0
Timepoint [1] 310992 0

Key inclusion criteria
BMI between 25 and 35
Minimum age
18 Years
Maximum age
60 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
Diabetic, pregnant or breast feeding

Study design
Purpose of the study
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Phase 0
Type of endpoint(s)
Statistical methods / analysis
Baseline demographic and clinical information will be summarized using standard descriptive statistics including means, medians, standard deviations, ranges, frequencies and percentages. Changes in outcomes will be analysed using paired t-tests with a two-tailed p-value <0.05 considered statistically significant. The primary analyses will be undertaken on all completing participants but analyses will also explore weight changes in those participants who exit the study early. Clinical trials demonstrating weight loss by a similar mechanism as is hypothesised for the NZ Extracts product have seen significant changes with 20-60 participants over an 8 week period. For this trial it is intended to recruit 100 participants with the aim that a least 60 will complete the trial. A sample size of 60 will enable an effect size for weight change of >0.4 to be detected as statistically significant (two-sided a=0.05) with greater than 80% power.

Recruitment status
Active, not recruiting
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment outside Australia
Country [1] 6388 0
New Zealand
State/province [1] 6388 0

Funding & Sponsors
Funding source category [1] 290044 0
Commercial sector/Industry
Name [1] 290044 0
Tuatara Natural Products Ltd
Address [1] 290044 0
30 Maxwell Rd
Blenheim 7240
Country [1] 290044 0
New Zealand
Funding source category [2] 290045 0
Government body
Name [2] 290045 0
Callaghan Innovation
Address [2] 290045 0
69 Gracefield Road
PO Box 31310
Lower Hutt 5040
Country [2] 290045 0
New Zealand
Primary sponsor type
Commercial sector/Industry
New Zealand Extracts Ltd
30 Maxwell Rd
Blenheim 7240
New Zealand
Secondary sponsor category [1] 288734 0
Name [1] 288734 0
Address [1] 288734 0
Country [1] 288734 0

Ethics approval
Ethics application status
Ethics committee name [1] 291754 0
Health and Disability Ethics Committees
Ethics committee address [1] 291754 0
Level 6
Deloitte House
10 Brandon St
Wellington 6011
Ethics committee country [1] 291754 0
New Zealand
Date submitted for ethics approval [1] 291754 0
Approval date [1] 291754 0
Ethics approval number [1] 291754 0

Brief summary
The primary purpose of this trial is to measure the acceptability of, and compliance with regular consumption of the health supplement Satisfax and its effect on body weight in overweight volunteers over a period of 8 weeks. We hypothesize that the regular consumption of Satisfax will lead to a loss of weight in overweight volunteers.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 51882 0
Dr Glenn Vile
Address 51882 0
New Zealand Extracts Ltd
PO Box 549
Blenheim 7240
Country 51882 0
New Zealand
Phone 51882 0
+64 21 734 706
Fax 51882 0
Email 51882 0
Contact person for public queries
Name 51883 0
Dr Glenn Vile
Address 51883 0
New Zealand Extracts Ltd
PO Box 549
Blenheim 7240
Country 51883 0
New Zealand
Phone 51883 0
+64 21 734 706
Fax 51883 0
Email 51883 0
Contact person for scientific queries
Name 51884 0
Dr Glenn Vile
Address 51884 0
New Zealand Extracts Ltd
PO Box 549
Blenheim 7240
Country 51884 0
New Zealand
Phone 51884 0
+64 21 734 706
Fax 51884 0
Email 51884 0

No information has been provided regarding IPD availability
Summary results
Have study results been published in a peer-reviewed journal?
Other publications
Have study results been made publicly available in another format?
Results – basic reporting
Results – plain English summary